Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2023 | How far away are we from implementing liquid biopsy approaches in GU cancers?

Name: How far away are we from implementing liquid biopsy approaches in GU cancers?
Uploaded: 2023-02-16T00:00:00Z
Duration: 1 min 40 s

Lucia Nappi • 16 Feb 2023

GU Cancers 2023

Bladder Cancer Genitourinary Cancer Prostate Cancer Testicular Cancer

Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, discusses the implementation of liquid biopsy approaches in GU cancer, including with miR-371 in testicular cancer. In bladder cancer, circulating tumor DNA (ctDNA) is under investigation to identify patients with residual disease following radical cystectomy and in prostate cancer there are various gene expression signatures being assessed to predict patient outcomes. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.